Winter was surprised to see its swift rise, given the variant it descended from - BA.2.86, or “Pirola” - packed nearly as many mutations, but never took off itself.
All that separated the two was a single change its cell-hacking spike protein - and while that mutation was likely linked to immune escape, “it wasn’t like a giant red flag that was going to make it a lot worse... but it was”.
As at this month, JN.1 was behind an estimated 86 per cent of cases in the US and around three quarters in the UK, with similar growth being seen across the Tasman.
Here, it swiftly added momentum to a Covid-19 wave that began building around the start of summer, on the back of waned population immunity.
“Toward the end of December, we were showing that it had a growth advantage that was about the same as BA.5, and that it would become the dominant variant in January,” Winter said.
“And that’s just what’s happened.”
While JN.1 didn’t appear to make people any sicker than the Omicron variants before it, that pattern could change as the virus continued to evolve.
The latest Omicron-targeted booster wasn’t yet available in New Zealand, despite being in use elsewhere – but experts say the current shot remained effective in preventing severe disease.
Meanwhile, ESR’s latest wastewater data still showed elevated levels of the virus across the country, with the summer wave following a plateau-like pattern.
“There is a slight downward trend since December following a relatively stable period over the last couple of months, but fluctuations in the data have been observed,” said Dr Joanne Hewitt, head of ESR’s Environmental Virology Laboratory.
Te Whatu Ora Health New Zealand reported 343 people in hospital with the virus as at last Sunday - up from 324 the week before.
Jamie Morton is a specialist in science and environmental reporting. He joined the Herald in 2011 and writes about everything from conservation and climate change to natural hazards and new technology.
